Overall, clinical outcomes among individuals with post-vaccination myocarditis and myopericarditis were mild, with no readmissions, diagnoses of heart failure, or death within 28 days following mRNA-1273 vaccination. Hence, further multinational studies and meta-analyses are required to investigate the true prevalence and risk stratification of myocarditis and pericarditis following mRNA-based COVID-19 vaccines.